However, the model's weight loss, low levels of blood lipids, and normal insulin sensitivity are not consistent with the clinical metabolic characteristics of NAFLD (Lau et al., 2018). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.